Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Phase I/II clinical trial to analyze safety and efficiency of intralesional application of
the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic
melanoma stage III/IV and unresectable metastasis.